Event Co-Sponsor
The KCSA Psychedelics Conference features live presentations and speakers who will address the various investment opportunities in psychedelic treatments for mental health disorders. The agenda highlights companies representing research, drug development, patient care delivery, integrated technology solutions, and patient support services that are crucial components of the reemerging psychedelic industry. Presenting companies include a variety of business models including drug developers, investment funds, care delivery treatment clinics, cGMP operators, and vertically integrated business models.
October 13th Agenda - Available for On-Demand Viewing
Small Pharma Inc.
TSX-V: DMT
Peter Rands, CEO
Dr Carol Routledge, Chief Scientific and Medical Officer
Awakn Life Sciences Corp.
OTCQB: AWKNF | NEO: AWKN
Anthony Tennyson, CEO
HMNC Brain Health
Private Company
Benedikt von Braunmühl, CEO
Maximilian Döbler, Head of Operations
Enveric Biosciences
NASDAQ: ENVB
Joseph Tucker, CEO
Mind Cure Health Inc.
OTCQX: MCURF | CSE: MCUR
Kelsey Ramsden, President & CEO
Field Trip Health Ltd.
NASDAQ: FTRP | TSX: FTRP
Joseph del Moral, Co-Founder & CEO
Nathan Bryson, Chief Scientific Officer
Novamind Inc.
OTCQB: NVMDF | CSE: NM
Yaron Conforti, CEO, Director, Co-Founder
BetterLife Pharma Inc.
OTCQB: BETRF | CSE: BETR
Ahmad Doroudian, CEO & Director
MYND Life Sciences Inc.
Pink: MYNDF | CSE: MYND
Dr. Lyle Oberg, CEO
FSD Pharma Inc.
NASDAQ: HUGE | CSE: HUGE
Anthony Durkacz, Founder, Interim CEO & Executive Co-Chairman of the Board
Dr. Lakshmi Kotra, CEO of Lucid
October 14th Agenda - Available for On-Demand Viewing
Mindset Pharma Inc.
OTCQB: MSSTF | CSE: MSET
James Lanthier, CEO
Joseph Araujo, Chief Scientific Officer
PsyBio Therapeutics Corp.
OTCQB: PSYBF | TSX-V: PSYB
Evan Levine, Co-Founder, CEO and Director
Psyched Wellness Ltd.
OTCQB: PSYCF | CSE: PSYC
Jeff Stevens, CEO
David Shisel, COO
Bright Minds Biosciences Inc.
OTCQB: BMBIF | CSE: DRUG
Ian McDonald, President & CEO
Josh Blacher, VP of Corporation Development
Fireside Chat
Amy Emerson, CEO, MAPS Public Benefit Corp
Moderated by Tim Regan, SVP, KCSA Strategic Communications
Lunch Panel - Investing in Psychedelics and CNS Treatments
Lindsay Hoover, Partner, JLS Fund
Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL), AdvisorShares Investments
Moderated by Tim Regan, SVP, KCSA Strategic Communications
Cybin Inc.
NYSE American: CYBN | NEO: CYBN
Doug Drysdale, CEO
Mydecine Innovations Group
Pink: MYCOF | NEO: MYCO
Joshua Bartch, CEO
NeonMind Biosciences Inc.
OTCQB: NMDBF | CSE: NEON
Rob Tessarolo, President & CEO
Numinus Wellness Inc.
TSX-V: NUMI
Payton Nyquvest, Founder & CEO
Tryp Therapeutics Inc.
OTCQB: TRYPF | CSE: TRYP
Luke Hayes, CFO
Wesana Health Holdings Inc.
OTCQB: WSNAF | CSE: WESA
Daniel Carcillo, CEO
Filament Health Corp.
OTCQB: FLHLF | NEO: FH
Ben Lightburn, CEO